Camisole

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Tuesday, November 7, 2023
DLBCL, The Year's Best Science Fiction: Eleventh Annual Collection, MD Anderson Cancer Center, FDA, NSCLC, NYSE, PIN, University, IHC, S&M, EST, CD22, G&A, Mitsubishi Tanabe Pharma, Society, ASH, Environment, SOHO, Growth, ADC, Clinical trial, Follicular lymphoma, KAAG1, Rituximab, Pancreatic cancer, Lung cancer, Safety, Therapy, American Society of Pediatric Hematology/Oncology, Patient, Immunohistochemistry, AXL, Sarcoma, Bank, Pharmaceutical industry, Video game, Fine chemical, Camisole

LAUSANNE, Switzerland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • Net product revenues were $14.3 million for the quarter ended September 30, 2023, compared to $21.3 million for the same quarter in 2022.
  • S&M expenses were $13.7 million for the quarter ended September 30, 2023, compared to $16.8 million for the same quarter in 2022.
  • G&A expenses were $9.4 million for the quarter ended September 30, 2023, compared to $19.6 million for the same quarter in 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss third quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Brown Schultz Sheridan & Fritz's Cami Grimm and Eric Wendler Graduate from Leadership Harrisburg Area 2023 Leadership Programs

Retrieved on: 
Monday, June 5, 2023
Pennsylvania State University, Human, Business development, Shippensburg University of Pennsylvania, Rotary International, BSSF, Business, Quality of life, LHA, Advisory board, Homelessness, Organization, Camisole, Business administration, CPA, Carlisle Area School District, EBP, Accounting, Commerce, Big Brothers Big Sisters, Management, Capital region, South Central Pennsylvania, Education

FREDERICK, Md., June 5, 2023 /PRNewswire-PRWeb/ -- Brown Schultz Sheridan & Fritz's (BSSF) Cami Grimm, CPA, Manager, and Eric Wendler, Director of Business Development, recently graduated from Leadership Harrisburg Area (LHA) 2023 leadership programs. Cami and Eric both graduated as part of a graduation ceremony at the Penn Harris Hotel in Camp Hill, Pennsylvania, on Tuesday, May 16, 2023.

Key Points: 
  • FREDERICK, Md., June 5, 2023 /PRNewswire-PRWeb/ -- Brown Schultz Sheridan & Fritz's (BSSF) Cami Grimm, CPA, Manager, and Eric Wendler, Director of Business Development, recently graduated from Leadership Harrisburg Area (LHA) 2023 leadership programs.
  • Cami Grimm graduated from LHA's Community Leadership Series Class of 2023.
  • "It was a privilege to participate in LHA's Community Leadership Series alongside others who are so dedicated to giving back," said Cami.
  • To learn more about LHA, the Community Leadership Series and/or the Executive Leadership Series, please visit https://www.leadershipharrisburg.org/ .

ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mitsubishi Tanabe Pharma, Workforce, Medicare (United States), DLBCL, KAAG1, Infrastructure Investment and Jobs Act, PSMA, Clinical trial, Medicare Part D, CD22, G&A, NSCLC, Lung cancer, Sale, IHC, B-cell lymphoma, Medicare, NYSE, Sarcoma, PIN, Group purchasing organization, AXL, Patient, Investment, National Medical Products Administration, Growth, ADC, GPO, S&M, Therapy, Safety, NMPA, Management, Risk management, Pharmaceutical industry, Vaccine, Renewable energy, Video game, Reinsurance, EU, Camisole

ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the first quarter 2023 and provided an updated corporate strategy.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the first quarter 2023 and provided an updated corporate strategy.
  • “2023 is a pivotal year for positioning ADC Therapeutics to capture the full potential value of our assets.
  • R&D expenses were $39.5 million for the quarter ended March 31, 2023, compared to $49.0 million for the same quarter in 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS

Retrieved on: 
Monday, December 12, 2022
Heme, Therapy, DLBCL, Lymphatic system, Immune system, PBD, Society, Biomarker, Patient, Cancer, ADC, Research, Biology, NYSE, Diffuse large B-cell lymphoma, FDA, Molecular biology, Nucleic acid thermodynamics, Multimedia, Loncastuximab tesirine, Control, SAN, Blood, Machine learning, ASH, Hodgkin lymphoma, Medical imaging, Fine chemical, Pharmaceutical industry, San Francisco Bay Area, Catriona lonca, Camisole

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 /PRNewswire/ -- Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans.

Key Points: 
  • The findings presented at ASH show promise in identifying biomarkers associated with response to lonca and also suggested mechanisms of resistance seen in non-responders, which may inform future drug combination research.
  • "We look forward to further exploration of these findings to determine their significance for healthcare providers trying to identify the most appropriate treatments for patients with DLBCL."
  • "ADC Therapeutics is a leader in the field of antibody-drug conjugates," said Mike Nolan , chief executive officer, Freenome.
  • The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Company, Lymphatic system, ADC, Hodgkin lymphoma, FDA, Investor, NYSE, Webcast, Conference, B-cell lymphoma, Therapy, Event, PBD, Diffuse large B-cell lymphoma, View, Technology, Control, Patient, Cancer, Fine chemical, San Francisco Bay Area, Camisole

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15th at 9:45 a.m. GMT.
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Pharmaceutical, Health, Oncology, UNC Kenan–Flagler Business School, Marketing, Hodgkin lymphoma, Delcath Systems, Growth, Williams College, Control, University of North Carolina at Greensboro, PBD, MBA, Liver, Law, Diffuse large B-cell lymphoma, Acute lymphoblastic leukemia, Immunogen, Cancer, NYSE, Lymphatic system, Human resources, Head, View, Hematologic disease, Political science, ADC, Sale, Technology, University, BA, Hope, General counsel, Compliance, Acute leukemia, Company, Novartis, Therapy, FDA, DLBCL, Acute myeloid leukemia, Patient, Hematology, Multiple sclerosis, University of Wisconsin–Madison, Malignancy, Myelodysplastic syndrome, Management, Fine chemical, Pharmaceutical industry, Camisole, San Francisco Bay Area

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Kristen Harrington-Smith as Chief Commercial Officer, effective November 17, 2022.
  • The Company also announced the appointment of Peter Graham as Chief Legal Officer, effective November 1, 2022.
  • We have complete conviction that Kristen is the right leader to maximize the potential of ZYNLONTA and take our commercial organization to the next level, said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
  • Most recently, she has served as Chief Commercial Officer of Immunogen where she has been responsible for building the commercial organization and preparing for the launch of its first commercial product.

ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022

Retrieved on: 
Monday, October 31, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Diffuse large B-cell lymphoma, Hodgkin lymphoma, PIN, Control, View, PBD, Time, Therapy, Lymphatic system, Patient, Cancer, ADC, NYSE, Investor, Company, FDA, Technology, B-cell lymphoma, Fine chemical, San Francisco Bay Area, Camisole

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 8, 2022 at 8:30 a.m.
  • ET to report financial results for the third quarter 2022 and provide business updates.
  • A live webcast of the call will be available under Events and Presentations in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, September 6, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Lymphatic system, Technology, Hodgkin lymphoma, Cancer, NYSE, View, Therapy, Morgan, PBD, LinkedIn, Control, Conference, Company, FDA, Twitter, ADC, Diffuse large B-cell lymphoma, Investor, Webcast, Event, Patient, Fine chemical, San Francisco Bay Area, Camisole

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanleys 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at Morgan Stanleys 20th Annual Global Healthcare Conference on Tuesday, September 13th at 11:45 a.m.
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics website, ir.adctherapeutics.com .
  • ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs).
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes

Retrieved on: 
Monday, August 15, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, FDA, U.S. Securities and Exchange Commission, ADC, Exercise, Forward-looking statement, NYSE, Technology, Growth, Cancer, Sale, Lymphatic system, Security (finance), SOFR, Patient, Therapy, Company, Twitter, Report, List of life sciences, Control, Diffuse large B-cell lymphoma, Hodgkin lymphoma, Morgan Stanley, Oaktree Capital Management, LinkedIn, IPO, PBD, Fine chemical, Camisole, Owl Rock, San Francisco Bay Area

Pursuant to the loan and guaranty agreement, the Company completed an initial drawdown of $120 million on August 15, 2022.

Key Points: 
  • Pursuant to the loan and guaranty agreement, the Company completed an initial drawdown of $120 million on August 15, 2022.
  • This amount was used by the Company to fund the cash consideration as part of the settlement of Deerfields senior secured convertible notes.
  • Up to two additional tranches in the amount of $27.5 million each can be drawn by the Company upon meeting certain conditions within 18 months.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022

Retrieved on: 
Tuesday, August 2, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, PIN, PBD, Time, View, Twitter, ADC, NYSE, Therapy, Control, Cancer, Technology, FDA, Company, Patient, LinkedIn, Lymphatic system, Diffuse large B-cell lymphoma, B-cell lymphoma, Investor, Hodgkin lymphoma, Fine chemical, San Francisco Bay Area, Camisole

ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 9, 2022 at 8:30 a.m.
  • ET to report financial results for the second quarter 2022 and provide business updates.
  • A live webcast of the call will be available under Events and Presentations in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com .
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.